Zinepra 10 Tablet SR is a sustained-release formulation combining Propranolol 40 mg and Flunarizine 10 mg, designed for the management of migraine prophylaxis and related vascular disorders. Propranolol, a non-selective beta-adrenergic blocker, exerts its therapeutic effect by reducing cardiac output and inhibiting beta-receptors in the central nervous system, thereby decreasing the frequency and severity of migraine attacks. Flunarizine, a calcium channel blocker with antihistaminic properties, contributes to migraine prevention by inhibiting calcium influx into vascular smooth muscle cells, stabilizing neuronal excitability, and reducing cerebral vasospasm. The sustained-release mechanism ensures a gradual and consistent release of active ingredients, enhancing patient compliance and minimizing peak-related side effects. Zinepra 10 Tablet SR is indicated for patients requiring long-term management of migraines, particularly those with comorbid hypertension or anxiety disorders where beta-blockade is beneficial. It should be used under medical supervision, with caution advised in patients with asthma, bradycardia, or heart block. Common adverse effects may include fatigue, dizziness, gastrointestinal disturbances, and mild hypotension. Regular monitoring of cardiovascular status is recommended during therapy. This combination offers a synergistic approach to migraine prophylaxis, improving quality of life for patients with recurrent migraine episodes.